Age (years) [median (range)] |
55 (21-73) |
Gender (male/female) (n) |
15/12 |
Diagnosis [n(%)] |
Acute myeloid leukemia |
12 (44.5) |
Acute lymphoblastic leukemia |
10 (37) |
Non-Hodgkin lymphoma |
3 (11.1) |
Multiple myeloma |
1 (3.7) |
Primary myelofibrosis |
1 (3.7) |
Pre-transplant Disease Status [n(%)] |
CR |
20 (74.1) |
PR |
3 (11.1) |
PD |
3 (11.1) |
SD |
1 (3.7) |
Donor Type [n(%)] |
MRD |
15 (55.6) |
MUD |
1 (3.7) |
MMRD |
1 (3.7) |
MMUD |
5 (18.5) |
Haploidentical |
5 (18.5) |
Neutrophil Engraftment (days) [median (range)] |
15 (10-32) |
Platelet Engraftment (days) [median (range)] |
16 (9-146) |
Previous Cytomegalovirus Reactivation [n(%)] |
23 (85.2) |
Previous Acute GvHD [n(%)] |
13 (48.1) |
Post-transplant Day [median (range)] |
55 (21-134) |
Grade [median (range)] |
2 (1-4) |
Previous Chronic GvHD [n(%)] |
6 (22.2) |
Post-transplant Day [median (range)] |
188 (126-586) |
Stage |
Limited [n(%)] |
4 (66.7) |
Extended [n(%)] |
2 (33.3) |